Trials / Unknown
UnknownNCT04614415
Clinical Investigation to Evaluate the Performance of Hyaluronic Acid for the Treatment of Hypertrophic Scars
Multicenter, Double Blind, Randomized, Controlled Clinical Investigation to Evaluate the Performance of Autocross-linked Hyaluronic Acid for the Treatment of Hypertrophic Scars
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Fidia Farmaceutici s.p.a. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The study includes two study groups, one involves treatment with auto-cross-linked Hyaluronic acid by intralesional and hypodermic injection, repeated after two weeks (T14), while the control arm provides an equal treatment but with isotonic saline solution. Enrolled patients will be randomized into 2 groups with an allocation of 2:1 in study treatment arm and control arm respectively. They will be evaluated using the POSAS scale before the treatment and re-evaluated at 30, 90 and 180 days after treatment. The scar evaluation will be completed by an ultrasound assessment at time 0 (T0), 30 (T30), T90 and T180 and the DLQI (Dermatology Life Quality Index) to be assessed at time 0 (T0), 30 (T30), 90 (T90) and 180 (T180). In subjects that will consent, a small surgical biopsy for an explorative evaluation of the scar tissue will be performed before (T0) and after treatment (T30) for a histological assessment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Autocrosslinked Hyaluronic aid | IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel. In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA |
| OTHER | placebo | The placebo consists in an isotonic saline solution (NaCl 0.9%) |
Timeline
- Start date
- 2020-01-14
- Primary completion
- 2024-06-30
- Completion
- 2024-12-31
- First posted
- 2020-11-04
- Last updated
- 2023-10-17
Locations
4 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT04614415. Inclusion in this directory is not an endorsement.